Cardiovasc Res:Kcnk3 功能障碍促进左心疾病相关肺动脉高压进展

2021-10-08 刘少飞 MedSci原创

众所周知,肺动脉高压 (PH) 是左心疾病 (LHD,第 2 组 PH) 的常见并发症,可导致右心室 (RV) 衰竭和死亡。在肺动脉高压(PAH,第 1 组 PH)中发现了 KCNK3 中的几个功能丧


众所周知,肺动脉高压 (PH) 是左心疾病 (LHD,第 2 组 PH) 的常见并发症,可导致右心室 (RV) 衰竭和死亡。在肺动脉高压(PAH,第 1 组 PH)中发现了 KCNK3 中的几个功能丧失(LOF)突变。此外,研究发现 KCNK3 功能障碍是肺血管和 RV 水平 PAH 的标志。然而,KCNK3 在 LHD 所致 PH 病理生物学中的作用尚不清楚。
研究方法:
该研究通过超声心动图、RV 导管插入术、组织学分析和分子生物学实验评估了 KCNK3 对 WT 和 Kcnk3-LOF 突变大鼠升主动脉缩窄 (AAC) 诱导的 PH 的作用。

研究结果:

发现 Kcnk3-LOF 突变对 AAC 中左心室 (LV) 代偿性向心肥厚的发展没有影响,而 AAC-Kcnk3 突变大鼠的左心房排空分数受损。 AAC 动物(WT 和 Kcnk3 突变的大鼠)继发于 AAC,并且 Kcnk3 突变的大鼠出现了比 WT 更严重的 PH。 AAC-Kcnk3 突变的大鼠发生 RV 和 LV 纤维化,与右心室和左心室中 Col1a1 mRNA 的增加相关。与AAC-WT相比,AAC-Kcnk3突变的大鼠发生严重的肺血管(肺动脉和肺静脉)重塑,伴有强烈的血管周围和支气管周围炎症、血管周围水肿、肺泡壁增厚和肺血管细胞增殖过度老鼠。最后,在 AAC-Kcnk3 突变大鼠的肺、右心室、左心室和左心房中,发现 Il-6 和骨膜蛋白表达强烈增加,肺 Ctnnd1 mRNA(编码 p120 连环蛋白)减少,有助于AAC-Kcnk3 突变大鼠的肺和心脏重构以及肺血管水肿的夸张。
研究启示
对于PAH突变KCNK3基因,其Kcnk3-LOF 是 AAC 导致的 PH 病理生物学中的关键事件,表明 Kcnk3 通道功能障碍可能在 LHD 导致的 PH 发展中发挥潜在的关键作用。在 LV 压力超负荷的背景下,该研究发现 Kcnk3-LOF 突变促进

(i) 肺内皮完整性的破坏,导致肺血管周围水肿和 PA 外膜重塑,

(ii) 炎症信号 (IL-6),导致 PASMC 增加 增殖促进肺血管和实质重塑。 (i) 和 (ii) 有助于增加肺血管阻力。

(iii) 心脏纤维化将 LV 舒张功能障碍与 LA 顺应性降低和肺静脉重构异常联系起来。

总之,这些事件有利于 Kcnk3 突变大鼠的 PH 加重和随之而来的 RV 肥大和功能障碍。 

文章出处:

Lambert M. Kcnk3 Dysfunction Exaggerates The Development Of Pulmonary Hypertension Induced By Left Ventricular Pressure Overload. Cardiovasc Res. 2021 Jan 23:cvab016. DOI: 10.1093/cvr/cvab016. Epub ahead of print. PMID: 33483721.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1939254, encodeId=4a33193925475, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Apr 28 17:51:17 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925398, encodeId=18c01925398d3, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 04 03:51:17 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421394, encodeId=e0a41421394f4, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Oct 09 14:51:17 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058582, encodeId=5933105858278, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Oct 08 12:19:26 CST 2021, time=2021-10-08, status=1, ipAttribution=)]
    2022-04-28 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1939254, encodeId=4a33193925475, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Apr 28 17:51:17 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925398, encodeId=18c01925398d3, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 04 03:51:17 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421394, encodeId=e0a41421394f4, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Oct 09 14:51:17 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058582, encodeId=5933105858278, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Oct 08 12:19:26 CST 2021, time=2021-10-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1939254, encodeId=4a33193925475, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Apr 28 17:51:17 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925398, encodeId=18c01925398d3, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 04 03:51:17 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421394, encodeId=e0a41421394f4, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Oct 09 14:51:17 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058582, encodeId=5933105858278, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Oct 08 12:19:26 CST 2021, time=2021-10-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1939254, encodeId=4a33193925475, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Apr 28 17:51:17 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925398, encodeId=18c01925398d3, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 04 03:51:17 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421394, encodeId=e0a41421394f4, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Oct 09 14:51:17 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058582, encodeId=5933105858278, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Oct 08 12:19:26 CST 2021, time=2021-10-08, status=1, ipAttribution=)]
    2021-10-08 仁术2021

    不错学习了

    0

相关资讯

Sci Rep:系统性硬化症胃黏膜凋亡和增殖因子的表达与疾病类型有关

这项研究数据表明sys1是SSc最“活跃”的增殖形式。Sys2特征是胶原蛋白沉积、表面上皮缺陷、广泛的凋亡和低增殖、GM萎缩和功能丧失。

Clinica Chimica Acta:microRNA-34a通过下调c-Met抑制人晶状体上皮细胞的增殖和迁移

microRNA (miRNAs)是一种内源性表达的非编码小RNA,通过与靶mRNA结合抑制蛋白质翻译

Cell Death Dis:荜茇酰胺,银屑病的潜在治疗选择!

银屑病是一种自身免疫性皮肤病;放大的细胞因子信号、异常分化及角质细胞凋亡缺陷所引起的慢性免疫应答反应,在介导角化细胞异常增生中起重要作用。从治疗的角度来看,具有强抗增殖和抗炎特性的分子或可取得一定疗效。本研究发现荜茇酰胺(Piperlongumine,PPL)处理可以通过诱导ROS介导的晚期细胞凋亡及线粒体膜电位的丧失来有效消除角质细胞的过度增殖及分化。此外,研究人员发现由于DNA断裂,细胞周期停

Dent Mater J:纳米羟磷灰石大小对成牙本质细胞样细胞MDPC-23增殖的影响

纳米羟磷灰石(nano-HAP)有望成为硬组织工程磷灰石的一种替代物。这篇研究的目的是为了评估nano-HAP颗粒对成牙本质细胞样细胞MDPC-23增殖的影响,并与常规羟磷灰石(c-HAP)相对照。

J Cell Mol Med:Sirtuin 5能够调控前列腺癌细胞的增殖、侵袭和迁移

Sirtuin 5(SIRT5)是一种NAD+依赖性的Ⅲ类蛋白去乙酰化酶,其在前列腺癌中的作用尚未见报道。

Urol Int:miR-155-5p通过靶向PEG3促进透明细胞肾细胞癌的细胞增殖和迁移

肾细胞癌(RCC)是成人最常见的肾脏肿瘤,占肾脏恶性肿瘤的3%,近年来其发病率一直在上升,据报道,2020年美国有73750例确诊病例,14830例死亡。由于肿瘤的侵袭性,缺乏早期发现,以及对临床治疗